Targeted Talks is a podcast series from Targeted Oncology featuring one-on-one conversations with leading oncologists about the issues shaping cancer care today. Each episode explores the real-world challenges clinicians face alongside discussions of emerging research across tumor types. Whether unpacking new data, translating conference highlights into clinical context, or addressing the practical realities of oncology practice, Targeted Talks delivers timely, actionable conversations designed for today's oncology professionals.
For more visit: https://www.targetedonc.com/podcasts (https://www.targetedonc.com/podcasts)
S8 Ep7: Dr Jhaveri on the FDA Approval of Imlunestrant Plus Abemaciclib for ESR1-Mutated Breast Cancer
Komal Jhaveri, MD, discusses the FDA approval of imlunestrant plus abemaciclib for ESR1-mutated breast cancer, EMBER-3 data, and what's next.
29 Sept 2026
S8 Ep6: Dr Herzberg on the Expanding Toolkit in KRAS-Mutant Non–Small Cell Lung Cancer
In this episode of Targeted Talks, Benjamin Herzberg, MD, discusses the evolving treatment landscape for KRAS-mutant non–small cell lung cancer (NSCLC). He explains why KRAS matters to all oncologists, since these mutations drive roughly 30% of NSCLC cases, and reviews why chemoimmunotherapy remains the first-line standard of care for now. He also covers how central nervous system metastases affect treatment planning and why close collaboration with pathology and upfront biomarker testing are essential. Herzberg then turns to the pan-RAS inhibitor daraxonrasib (Rasonque), recently approved in pancreatic cancer, and explains why lung cancer clinicians should pay attention. He discusses its published lung cancer data, which show response rates and durability similar to those in pancreatic cancer, as well as the ongoing phase 3 trial vs docetaxel. He also discusses zoldonrasib, a G12D-specific inhibitor with a favorable tolerability profile, and the idea of a "RAS toolkit" of pan-RAS and allele-specific agents. He closes with the biggest unmet needs, including driver-negative disease and resistance to targeted therapy, and what excites him most: molecular glues and other novel drug modalities, including MTAP/PRMT5 inhibitors.
24 Sept 2026
S8 Ep5: ASTRO 2026 Preview: Dr Raj Singh on De-Escalation, Brain Metastases, and What's Next in Radiation Oncology
Ahead of the 2026 ASTRO Annual Meeting, Dr Raj Singh of Baptist Health joins the podcast to break down the studies he's watching most closely. The conversation opens with a pooled analysis of 3 phase 2 trials using FMISO PET imaging to identify hypoxic tumor regions and select patients with HPV-positive head and neck cancer who may safely de-escalate radiation dose, and Singh discusses what it would take to move this biomarker-driven approach beyond a single high-volume academic center. He then turns to updated C-POST data on the timing of cemiplimab initiation after radiotherapy in high-risk cutaneous squamous cell carcinoma, and to Alliance A071801, a phase 3 trial comparing single-fraction vs fractionated stereotactic radiosurgery to the resection cavity after brain metastasis surgery, including why patient-reported cognitive and emotional well-being end points matter alongside recurrence-free survival.
The discussion moves to two practice-shaping trials in small cell lung cancer: MAVERICK, which found no overall survival benefit for prophylactic cranial irradiation over MRI surveillance alone in limited-stage disease, and NRG CC009, comparing radiosurgery with hippocampal-avoidance whole brain radiotherapy plus memantine for patients with limited brain metastatic disease. Singh explains how these results may accelerate an already-underway shift away from whole brain radiotherapy. The episode closes with a look at TRIDENT, a tumor-treating fields trial in newly diagnosed glioblastoma that missed its primary end point, and what subgroup data might still reveal—plus Singh's broader take on radiation oncology's shift toward patient-reported, quality-of-life-focused outcomes.
Who has been a guest on Targeted Talks
Names identified in recent episode analyses. Showing up to five guests.
Alfred L Garfall MD
David A Russler-Germain
Aditya Bardia
Douglas Flora MD LSSBB FACCC
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
2,026,423
Score snapshot 15 Sept 2025
Podcast Authority Score: 47 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
48
Social presence
0
YouTube
86
Engagement
30
Contact Targeted Talks
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Questions about Targeted Talks
Who hosts Targeted Talks?
Benjamin Garmezy MD host the show. Published by Targeted Oncology.
How often do new episodes come out?
The show publishes daily, based on its RSS feed.
Does Targeted Talks take guests?
Yes. Guests have been identified in episode analyses.
Host of Targeted Talks?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
